lurasidone / Generic mfg. - LARVOL DELTA

Female Sexual Dysfunction Induced by Second-Generation Antipsychotic Drugs-A Disproportionality Analysis Based on the FAERS Database. (PubMed, Schizophr Bull) - "This pharmacovigilance study highlights significant associations between specific SGAs and female sexual dysfunction. Disproportionality signals vary by drug, symptom type, and prolactin-related mechanisms. Clinicians should consider sexual side effects in treatment decisions and monitor patients accordingly. Further prospective studies are warranted."

Journal • CNS Disorders • Mental Retardation • Psychiatry • Sexual Disorders

Treatment of bipolar depression: results from a comprehensive network meta-analysis and updated systematic review. (PubMed, Eur Neuropsychopharmacol) - "The original NMA showed that olanzapine plus fluoxetine, quetiapine, olanzapine, lurasidone, lumateperone, cariprazine, and lamotrigine were more efficacious than placebo in reducing depressive symptoms in BD with good confidence. The complementary systematic review identified 24 clinical trials, seven of which had published results suitable for meta-analysis; the remaining 17 studies were either ongoing or completed with no available results. Collectively, the NMA and systematic review findings can inform evidence-based care and the development of international treatment guidelines for bipolar depression."

Journal • Retrospective data • Review • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Improving Cognition in Bipolar Disorder: A Systematic Review of Current Pharmacological and Nutraceutical Approaches. (PubMed, Neuropsychobiology) - "These results suggest possible approaches for improving cognitive functioning in individuals with BD. Nevertheless, the inconsistency in outcomes and differences in study methodologies highlight the need for larger, rigorously controlled trials with uniform cognitive evaluations to confirm these findings and to assess their clinical relevance."

Journal • Review • Alzheimer's Disease • Bipolar Disorder • CNS Disorders • Cognitive Disorders • Mood Disorders • Psychiatry

Lurasidone in Schizophrenia Management: A Comprehensive 12-Week Post-Marketing Surveillance Study in Chinese Patients. (PubMed, Neuropsychiatr Dis Treat) - P | "Shanghai Clinical Research Center for Mental Health (SCRC-MH) NCT04432688. URL: www.smhc.org.cn/."

Journal • P4 data • CNS Disorders • Depression • Mood Disorders • Psychiatry • Schizophrenia

Antipsychotics in Children and Adolescents with Schizophrenia-Spectrum Disorders: A Systematic Review, Meta-Analysis, and Long-Term Prospective Evidence. (PubMed, J Child Adolesc Psychopharmacol) - "Several SGAs produce short-term symptom reductions versus placebo in children and adolescents with schizophrenia-spectrum disorders, with heterogeneity in TEAE risk across agents. Evidence for long-term maintenance and continuation remains limited, underscoring the need for adequately powered randomized continuation trials to guide sustained treatment in this population."

Journal • Retrospective data • Review • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

Real-world outcomes of lurasidone augmentation for treatment-resistant bipolar depression: a retrospective observational analysis. (PubMed, Front Psychiatry) - "However, remission rates remained low, underscoring the need for further research. In this perspective, lurasidone may contribute to more individualized treatment strategies for difficult-to-treat patients, although confirmatory studies are required to better define its role within precision psychiatry."

Journal • Real-world evidence • Retrospective data • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

fMRI-guided V1-targeted rTMS improves depressive symptoms in adolescents and young adults with bipolar disorder: a double-blind randomized controlled trial. (PubMed, BMC Med) - P=N/A | "The study preliminarily demonstrated that the navigated rTMS precisely targeting the V1-OFC circuit may be a safe and potentially effective intervention for adolescents and young adults with BD-D."

Journal • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Dose-response considerations in transdiagnostic antidepressant effects of lurasidone: response to Chen et al: commentary, Ghenciulescu & De Giorgi. (PubMed, Br J Psychiatry) - No abstract available

Journal • CNS Disorders • Psychiatry • Schizophrenia

Lurasidone Sub-Chronic Treatment During Adolescence Modulates Inflammatory and Inositol-Related Metabolic Pathways in the Prefrontal Cortex of Adult Male Rats Exposed to Prenatal Stress. (PubMed, Biomolecules) - "In parallel, LUR administration itself modulated Inositol-related metabolic pathways. Overall, these findings suggest that LUR adolescent treatment may counteract some PNS-induced alterations, supporting adolescence as a critical window for early preventive strategies with translational relevance for stress-related neuropsychiatric disorders."

Journal • Preclinical • CNS Disorders • Inflammation • Mental Retardation • Psychiatry • CXCL8

An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (clinicaltrials.gov) - P4 | N=5 | Terminated | Sponsor: Ohio State University | N=60 ➔ 5 | Trial completion date: Jun 2026 ➔ Jan 2026 | Recruiting ➔ Terminated; Not able to recruit enough subjects

Enrollment change • Trial completion date • Trial termination • CNS Disorders • Inflammation • Psychiatry • Schizophrenia

Prolonged QTc Interval Normalization After Switch to Lurasidone: A Case Series. (PubMed, J Clin Psychopharmacol) - "This case series demonstrated that switching to lurasidone reduced QTc prolongation induced by other antipsychotics or antidepressants. Lurasidone may lower the risk of sudden cardiac death in patients with psychiatric disorders by shortening QTc intervals."

Journal • Cardiovascular • CNS Disorders • Mental Retardation • Psychiatry

Physiologically Based Pharmacokinetic Modeling of Lurasidone, an Antipsychotic Drug: Impact of CYP3A4 Polymorphisms and Hepatic Impairment on Exposure and Dose Optimization. (PubMed, J Clin Pharmacol) - "This PBPK model offers a quantitative strategy for individualizing lurasidone dosing based on genotype and hepatic function. It provides a valuable precision dosing tool to ensure safety and efficacy in vulnerable patient populations."

Journal • PK/PD data • Bipolar Disorder • CNS Disorders • Depression • Hepatology • Psychiatry • Schizophrenia • CYP3A4

Lurasidone continuation in real-world clinical cases in Japan: retrospective study of factors associated with six-month persistence. (PubMed, Ann Gen Psychiatry) - "This is the first known study to evaluate real-world lurasidone persistence in patients in Japan. The findings indicate that both pharmacodynamic compatibility and early-phase treatment can enhance persistence. The insights obtained underscore the importance of individualized treatment planning, though require further validation by use of prospective, multi-center studies."

Journal • Real-world evidence • Retrospective data • CNS Disorders • Psychiatry • Schizophrenia

Antipsychotic treatment patterns and cardiometabolic medicine use: current real-world evidence. (PubMed, Epidemiol Psychiatr Sci) - "Use of cardiometabolic medicines is increased among people on long-term antipsychotic treatment. These results highlight the need for active monitoring for cardiometabolic adverse effects, with antipsychotic cessation where possible, or timely interventions to limit morbidity."

HEOR • Journal • Real-world evidence • Retrospective data • Cardiovascular • CNS Disorders • Metabolic Disorders

Use of antipsychotics in children and adolescents in Spain, 2015-2023: a real-world, population-based study. (PubMed, Span J Psychiatry Ment Health) - "AP prescriptions and patients treated among Spanish youth increased significantly between 2015 and 2023, with notable differences by age and sex. While total CED rose, treatment intensity per patient remained relatively stable. Future studies should investigate the clinical indications for these prescriptions as well as the outcomes associated with AP use in children and adolescents."

Journal • Real-world evidence • CNS Disorders

Reversible Lurasidone-Induced Tardive Retrocollis Managed With Aripiprazole. (PubMed, Am J Ther) - No abstract available

Journal

Bipolar major depression: A comprehensive review of pharmacotherapy. (PubMed, Nurse Pract) - "Effective options include quetiapine, lurasidone, and olanzapine-fluoxetine...Antidepressant monotherapy is discouraged. A patient-centered approach optimizing efficacy, safety, and stability is essential."

Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Lurasidone and Fluvoxamine Combination in Eating Disorders with Comorbid Obsessive-Compulsive Disorder: Preliminary Evidence from an Observational Study. (PubMed, Med Sci (Basel)) - "Within the constraints of this small, all-female inpatient cohort, the findings illustrate directional, time-related changes compatible with global rehabilitation effects rather than drug-specific efficacy. The study demonstrates the feasibility-and methodological challenges-of applying Bayesian longitudinal modeling to incomplete clinical datasets. Future randomized or adaptive trials incorporating objective endpoints and data-quality pipelines are warranted to test whether serotonergic-dopaminergic-σ-1 synergy provides genuine clinical benefit in the AN-OCD spectrum."

Journal • Observational data • Anorexia • CNS Disorders • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry

Ultrafast solvent removal delivers high-loading of amorphous small-molecule drugs in polymeric microspheres with predictable in vivo performance. (PubMed, J Control Release) - "This model accurately predicted the complete in vivo pharmacokinetic profiles of distinct formulations based solely on their in vitro release data, with prediction errors for key pharmacokinetic parameters (Cₘₐₓ and AUC) falling within the stringent ±10% regulatory benchmark. By directly linking a precisely controlled manufacturing process to predictable in vivo outcomes, the flow-solidify platform represents a robust process-performance linkage, offering a practical route to accelerate the development of next-generation long-acting injectable microsphere formulations for poorly water-soluble small molecule drugs."

Journal • Preclinical

Drug utilisation of antipsychotics and lithium in Sweden 2008-2021 - a nationwide study of children aged 5-17 years. (PubMed, Eur Child Adolesc Psychiatry) - "Risperidone is the only antipsychotic approved for younger children. Aripiprazole is approved for older children, ziprasidone and lurasidone for adolescents...In girls aged 12-17, aripiprazole and quetiapine were most common...The use of antipsychotics has increased, with the proportion of girls starting treatment at the end of study period exceeding that of boys. A considerable proportion of prescriptions was off-label, even when considering national guidelines."

Journal • CNS Disorders • Mental Retardation • Pediatrics • Psychiatry

Substance-Specific Treatment Responses and Resistance Patterns in Induced Psychoses: A Scoping Review of Antipsychotic Efficacy. (PubMed, Healthcare (Basel)) - "Randomized trials showed comparable efficacy between risperidone and haloperidol for cannabis-induced psychosis, and between quetiapine and haloperidol for methamphetamine-induced psychosis. Case series suggested potential benefits of third-generation antipsychotics such as lurasidone and cariprazine...While conventional antipsychotics appear effective for cannabis- and methamphetamine-related presentations, other substances remain virtually unstudied. Substantial evidence gaps and limited methodological quality highlight urgent research needs."

Journal • Review • CNS Disorders • Psychiatry • Schizophrenia

Treatment of depressive episodes with mixed features: A systematic review and meta-analysis. (PubMed, Gen Hosp Psychiatry) - "Limited but consistent RCT evidence supports lurasidone and ziprasidone for mixed-feature depression, while other interventions showed no clear benefit. Standardized diagnostic definitions and additional high-quality trials are essential to refine therapeutic recommendations and reduce heterogeneity."

Journal • Retrospective data • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

SMART-BD: Sequential Multiple Assignment Randomized Trial for Bipolar Depression (clinicaltrials.gov) - P4 | N=2726 | Active, not recruiting | Sponsor: Massachusetts General Hospital | Recruiting ➔ Active, not recruiting

Enrollment closed • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Food for thought: re-emergence of tardive dyskinesia amid nutritional rehabilitation of atypical anorexia nervosa; a case report. (PubMed, J Eat Disord) - "Nutritional rehabilitation likely has an impact on the metabolism of certain antipsychotic medications including lurasidone. More research is needed involving patients recovering from a restrictive eating disorder who are on antipsychotic medications and the frequency of increased side effects, including tardive dyskinesia, with refeeding."

Journal • Anorexia • Bipolar Disorder • CNS Disorders • Mood Disorders • Movement Disorders • Psychiatry

Post-lanosterol inhibition profile based classification of commonly used prescription medications. (PubMed, Transl Psychiatry) - "Using LC-MS/MS we measured 13 post-lanosterol intermediates in control, DHCR7 +/- and DHCR7-/- human dermal fibroblasts exposed to cariprazine, nebivolol, rotigotine, buspirone, lurasidone, fluoxetine, hydroxyzine, amiodarone, spiroxamine, vilazodone and ziprasidone. In addition, DHCR7 +/- fibroblasts responded with greater sterol profile disruptions to all medications, while DHCR7 fibroblasts from patients with Smith-Lemli-Opitz syndrome showed generally a more plateaued response. Knowing the inhibition profile-based classification of medications that have a sterol inhibiting side effect might ultimately translate into safety recommendations during pregnancy and could be critical for new drug development."

Journal • DHCR7